P A Marks

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors
    Leonard A Cohen
    Div Nutrition and Endocrinology, American Health Foundation, Valhalla, NY 10595, USA
    Anticancer Res 22:1497-504. 2002
  2. ncbi request reprint Histone deacetylase inhibitors: discovery and development as anticancer agents
    Paul A Marks
    Memorial Sloan Kettering Cancer Center, Cell Biology Program, Sloan Kettering Institute for Cancer Research, New York City, New York 10021, USA
    Expert Opin Investig Drugs 14:1497-511. 2005
  3. pmc Thioredoxin in cancer--role of histone deacetylase inhibitors
    Paul A Marks
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Semin Cancer Biol 16:436-43. 2006
  4. pmc The American Society for Clinical Investigation--the first 100 years
    Paul A Marks
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Clin Invest 118:1223-4. 2008
  5. ncbi request reprint Discovery and development of SAHA as an anticancer agent
    P A Marks
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Oncogene 26:1351-6. 2007
  6. pmc Histone deacetylase inhibitors: Potential in cancer therapy
    P A Marks
    Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Cell Biochem 107:600-8. 2009
  7. ncbi request reprint Histone deacetylase inhibitors in programmed cell death and cancer therapy
    Paul A Marks
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cell Cycle 4:549-51. 2005
  8. pmc The clinical development of histone deacetylase inhibitors as targeted anticancer drugs
    Paul A Marks
    Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, Cell Biology and Genetics Program, 1275 York Ave, New York, NY 10065, USA
    Expert Opin Investig Drugs 19:1049-66. 2010
  9. pmc Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions
    Paul A Marks
    Cell Biology and Genetics Program, Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Biochim Biophys Acta 1799:717-25. 2010
  10. ncbi request reprint Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug
    Paul A Marks
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Nat Biotechnol 25:84-90. 2007

Collaborators

Detail Information

Publications58

  1. ncbi request reprint Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors
    Leonard A Cohen
    Div Nutrition and Endocrinology, American Health Foundation, Valhalla, NY 10595, USA
    Anticancer Res 22:1497-504. 2002
    ..The results of this animal model study indicate that SAHA, when fed in the diet, serves as both a chemopreventive and chemotherapeutic agent in the absence of any detectable side effects...
  2. ncbi request reprint Histone deacetylase inhibitors: discovery and development as anticancer agents
    Paul A Marks
    Memorial Sloan Kettering Cancer Center, Cell Biology Program, Sloan Kettering Institute for Cancer Research, New York City, New York 10021, USA
    Expert Opin Investig Drugs 14:1497-511. 2005
    ..HDAC inhibitors can induce cancer cell death, whereas normal cells are relatively resistant to HDAC inhibitor-induced cell death...
  3. pmc Thioredoxin in cancer--role of histone deacetylase inhibitors
    Paul A Marks
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Semin Cancer Biol 16:436-43. 2006
    ..Up-regulation of TBP-2 and decrease of Trx may contribute to the sensitivity of many hematologic and solid tumors to anti-cancer activity of HDACi...
  4. pmc The American Society for Clinical Investigation--the first 100 years
    Paul A Marks
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Clin Invest 118:1223-4. 2008
    ....
  5. ncbi request reprint Discovery and development of SAHA as an anticancer agent
    P A Marks
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Oncogene 26:1351-6. 2007
    ..A new drug application has been approved for SAHA (vorinostat) treatment of cutaneous T-cell lymphoma...
  6. pmc Histone deacetylase inhibitors: Potential in cancer therapy
    P A Marks
    Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Cell Biochem 107:600-8. 2009
    ..The first HDACi approved by the FDA for cancer therapy is suberoylanilide hydroxamic acid (SAHA, vorinostat, Zolinza), approved for treatment of cutaneous T-cell lymphoma...
  7. ncbi request reprint Histone deacetylase inhibitors in programmed cell death and cancer therapy
    Paul A Marks
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cell Cycle 4:549-51. 2005
    ..In this review, we discuss the study of HDAC inhibitors in cell death and cancer research, the implications of our recent findings, and some outstanding questions that need to be addressed...
  8. pmc The clinical development of histone deacetylase inhibitors as targeted anticancer drugs
    Paul A Marks
    Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, Cell Biology and Genetics Program, 1275 York Ave, New York, NY 10065, USA
    Expert Opin Investig Drugs 19:1049-66. 2010
    ..Histone deacetylase (HDAC) inhibitors are being developed as a new, targeted class of anticancer drugs...
  9. pmc Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions
    Paul A Marks
    Cell Biology and Genetics Program, Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Biochim Biophys Acta 1799:717-25. 2010
    ..The HDACi are being developed as anti-cancer drugs and have therapeutic potential for many non-oncologic diseases...
  10. ncbi request reprint Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug
    Paul A Marks
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Nat Biotechnol 25:84-90. 2007
    ..A new drug application was approved by the US Food and Drug Administration for vorinostat for treatment of cutaneous T-cell lymphoma. More potent analogs of SAHA have shown unacceptable toxicity...
  11. ncbi request reprint Two cytodifferentiation agent-induced pathways, differentiation and apoptosis, are distinguished by the expression of human papillomavirus 16 E7 in human bladder carcinoma cells
    V M Richon
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 57:2789-98. 1997
    ....
  12. ncbi request reprint Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase
    L M Butler
    Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 7:962-70. 2001
    ..CONCLUSIONS: The findings suggest that pyroxamide may be a useful agent for the treatment of malignancy and that induction of p21/WAF1 in transformed cells by pyroxamide may contribute to the antitumor effects of this agent...
  13. ncbi request reprint Histone deacetylase inhibitors as new cancer drugs
    P A Marks
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Curr Opin Oncol 13:477-83. 2001
    ..Several structurally different histone deacetylase inhibitors are in phase I or II clinical trials in patients with cancers...
  14. pmc A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
    V M Richon
    Cell Biology Program, Memorial Sloan Kettering Cancer Center 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 95:3003-7. 1998
    ..These studies show that the second-generation HPCs, unlike HMBA, are potent inhibitors of HDAC activity. In this sense, HMBA and the second-generation HPCs appear to induce differentiation by different pathways...
  15. pmc Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation
    V M Richon
    DeWitt Wallace Research Laboratory, Cell Biology Program, Memorial Sloan Kettering Cancer Center and Graduate School of Medical Sciences of Cornell Medical School, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 97:10014-9. 2000
    ..Thus, the present findings indicate that the induction of p21(WAF1) by SAHA is regulated, at least in part, by the degree of acetylation of the gene-associated histones and that this induced increase in acetylation is gene selective...
  16. pmc Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors
    J S Ungerstedt
    Cell Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 102:673-8. 2005
    ..Thus, Trx, independent of the caspase apoptotic pathway, is an important determinant of resistance of cells to HDACi-induced cell death...
  17. pmc Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia
    L Z He
    Molecular Biology Program and Department of Pathology, Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Division, Graduate School of Medical Sciences, Cornell University, New York, New York 10021, USA
    J Clin Invest 108:1321-30. 2001
    ..In vivo, HDACIs induced accumulation of acetylated histones in target organs. Strikingly, this combination of agents induced leukemia remission and prolonged survival, without apparent toxic side effects...
  18. ncbi request reprint The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid
    D C Coffey
    Department of Pediatrics, Joan and Sanford I. Weill Graduate School of Medical Sciences of Cornell University, New York, New York, USA
    Cancer Res 61:3591-4. 2001
    ..Treatment was accompanied by mild weight loss in all groups except the lowest dose of CBHA. Our results suggest HDACIs alone or combined with retinoids may have therapeutic utility for neuroblastoma...
  19. pmc Cloning and characterization of a histone deacetylase, HDAC9
    X Zhou
    Cell Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 98:10572-7. 2001
    ..In the present study, we have identified HDAC9 and a number of alternatively spliced isoforms of HDAC9 with potentially different biological activities...
  20. ncbi request reprint Histone deacetylase inhibitors: molecular mechanisms of action
    W S Xu
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Oncogene 26:5541-52. 2007
    ..The plurality of mechanisms of HDACi-induced cell death reflects both the multiple substrates of HDACs and the heterogeneous patterns of molecular alterations present in different cancer cells...
  21. ncbi request reprint The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells
    P N Munster
    Program in Cell Biology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 61:8492-7. 2001
    ..SAHA and other HDAC inhibitors are currently in Phase I clinical trials. These findings may impact the clinical use of these drugs...
  22. ncbi request reprint Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells
    P A Marks
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Natl Cancer Inst 92:1210-6. 2000
    ..The hydroxamic acid-based HPCs are potentially effective agents for cancer therapy and, possibly, cancer chemoprevention...
  23. pmc Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor
    Weisheng Xu
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 103:15540-5. 2006
    ..Identifying these differences can have predictive value in assessing therapeutic response and identifying targets to enhance therapeutic efficacy...
  24. pmc Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1
    C Y Gui
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 101:1241-6. 2004
    ..Thus, this study identifies effects of SAHA on p21(WAF1)-associated proteins that explain, at least in part, the selective effect of HDACi in altering gene expression...
  25. ncbi request reprint Histone deacetylase inhibitors
    Paul A Marks
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Adv Cancer Res 91:137-68. 2004
    ..2001; Kelly et al., 2002a,b; Piekarz et al., 2001; Wozniak et al., 1999)...
  26. pmc Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents
    Mandana Namdar
    Cell Biology Program, Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 107:20003-8. 2010
    ..DDIT3 induction is further increased when tubacin is combined with SAHA. These findings point to mechanisms by which HDAC6-selective inhibition can enhance the efficacy of certain anti-cancer agents in transformed cells...
  27. ncbi request reprint Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid
    William Kevin Kelly
    Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nat Clin Pract Oncol 2:150-7. 2005
    ..SAHA is one of the HDAC inhibitors most advanced in development. It is in phase I and II clinical trials for patients with both hematologic and solid tumors...
  28. pmc Identification of a transcriptional repressor related to the noncatalytic domain of histone deacetylases 4 and 5
    X Zhou
    Cell Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center and Graduate School of Medical Sciences, Cornell University Medical School, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 97:1056-61. 2000
    ..HDAC inhibitors do not reverse transcriptional repression mediated by Gal4-HDRP. Thus, HDRP is a transcriptional repressor and can repress transcription in the presence of HDAC inhibitors...
  29. pmc Histone deacetylase 4 associates with extracellular signal-regulated kinases 1 and 2, and its cellular localization is regulated by oncogenic Ras
    X Zhou
    Cell Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center and Graduate School of Medical Sciences, Cornell University Medical School, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 97:14329-33. 2000
    ..Our results provide evidence that protein kinase activity is present in a protein complex with HDAC4 and directly links the Ras-MAPK signal transduction pathway to a mechanism for chromatin remodeling (i.e., histone deacetylation)...
  30. pmc HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation
    R B Parmigiani
    Cell Biology and Molecular Biology Programs, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 105:9633-8. 2008
    ..Thus, HDAC6 and Prx are targets for modulating intracellular redox status in therapeutic strategies for disorders as disparate as cancers and neurodegenerative diseases...
  31. ncbi request reprint Histone deacetylase inhibitors: from target to clinical trials
    William K Kelly
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Expert Opin Investig Drugs 11:1695-713. 2002
    ..Several HDAC inhibitors are currently in clinical trials as anticancer agents and, in particular, hydroxamic acid-based HDAC inhibitors have shown activity against cancers at well-tolerated doses...
  32. pmc Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair
    J H Lee
    Cell Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 107:14639-44. 2010
    ..This DNA damage is associated with cancer cell death. These findings can explain, in part, the selectivity of vorinostat in causing cancer cell death at concentrations that cause little or no normal cell death...
  33. ncbi request reprint Histone deacetylase inhibitors selectively suppress expression of HDAC7
    Milos Dokmanovic
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Mol Cancer Ther 6:2525-34. 2007
    ..Selective down-regulation of HDAC7 protein may serve as a marker of response of tumors to HDACi...
  34. pmc Apoptotic and autophagic cell death induced by histone deacetylase inhibitors
    Yufang Shao
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 101:18030-5. 2004
    ..Induction of autophagic cell death by HDAC inhibitors has clear clinical implications in treating cancers with apoptotic defects...
  35. ncbi request reprint Cloning of the cDNA encoding phenylalanyl tRNA synthetase regulatory alpha-subunit-like protein whose expression is down-regulated during differentiation
    X Zhou
    Cell Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center and Graduate School of Medical Sciences, Cornell University Medical School, New York, NY 10021, USA
    Gene 233:13-9. 1999
    ..The level of PheRS alpha-subunit-like mRNA is regulated during differentiation but not during cell cycle progression...
  36. ncbi request reprint Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously
    Wm Kevin Kelly
    Genitourinary Oncology Service, Departments of Medicine, Memorial Sloan Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, New York 10021, USA
    Clin Cancer Res 9:3578-88. 2003
    ..To evaluate the safety, pharmacokinetics, and biological activity of suberoylanilide hydroxamic acid (SAHA) administered by 2-h i.v. infusion in patients with advanced cancer...
  37. pmc Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
    William Kevin Kelly
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, NY 10021, USA
    J Clin Oncol 23:3923-31. 2005
    ..To determine the safety, dosing schedules, pharmacokinetic profile, and biologic effect of orally administered histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with advanced cancer...
  38. ncbi request reprint Histone deacetylases
    Paul A Marks
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Curr Opin Pharmacol 3:344-51. 2003
    ..Results of clinical trials with several of these agents have indicated that they are well tolerated at doses that have anti-tumour activity...
  39. pmc The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin
    Lisa M Butler
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 99:11700-5. 2002
    ....
  40. ncbi request reprint The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA)
    Paul A Marks
    Memorial Sloan Kettering Cancer Center, New York City, New York 10021, USA
    Cell Cycle 3:534-5. 2004
    ..Gui et al. have identified effects of SAHA on p21(WAF1) promotor associated proteins that explain, at least in part, the selective effects of HDAC in altering gene expression...
  41. ncbi request reprint Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro
    Martha C Kutko
    Department of Pediatric Surgery, Sloan Kettering Institute and Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 9:5749-55. 2003
    ..The effects of two of these agents, suberoylanilide hydroxamic acid (SAHA) and suberoyl-3-aminopyridineamide hydroxamic acid (pyroxamide), were investigated for their growth-suppressive effects on rhabdomyosarcoma (RMS) cells...
  42. ncbi request reprint Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
    M S Finnin
    Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nature 401:188-93. 1999
    ..These structures also suggest a mechanism for the deacetylation reaction and provide a framework for the further development of HDAC inhibitors as antitumour agents...
  43. pmc Cloning of a D-type cyclin from murine erythroleukemia cells
    H Kiyokawa
    DeWitt Wallace Research Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY
    Proc Natl Acad Sci U S A 89:2444-7. 1992
    ..5-kilobase CYL2 transcript changes its expression during the cell cycle with a broad peak through G1 and S phases and a decrease in G2/M phases. The present findings suggest that CYL2 plays a role in the G1 to S phase progression...
  44. ncbi request reprint Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects
    Wei Sheng Xu
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 65:7832-9. 2005
    ..The present findings indicate that the HDAC inhibitor could exert antitumor effects by inducing polyploidy, and this effect is more marked in transformed cells with nonfunctioning p21WAF1 or p53 genes...
  45. ncbi request reprint Histone deacetylase inhibitors: overview and perspectives
    Milos Dokmanovic
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mol Cancer Res 5:981-9. 2007
    ..A hypothesis is presented to explain the relative resistance of normal cells to HDACi-induced cell death...
  46. ncbi request reprint Prospects: histone deacetylase inhibitors
    Milos Dokmanovic
    Memorial Sloan Kettering Cancer Center, Cell Biology Program, Sloan Kettering Institute for Cancer Research New York City, New York 10021, USA
    J Cell Biochem 96:293-304. 2005
    ..The answers to these questions will have therapeutic importance since we will identify targets for enhancing the efficacy and safety of HDACi...
  47. ncbi request reprint Histone deacetylase inhibitors: development as cancer therapy
    Paul A Marks
    Cell Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, USA
    Novartis Found Symp 259:269-81; discussion 281-8. 2004
    ....
  48. pmc A man who has made his Marks on science
    Karen Honey
    J Clin Invest 116:2833. 2006
  49. ncbi request reprint Molecular sequelae of histone deacetylase inhibition in human malignant B cells
    Nicholas Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Blood 101:4055-62. 2003
    ....
  50. pmc Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease
    Emma Hockly
    Medical and Molecular Genetics, Guy s, King s and St Thomas School of Medicine, King s College London, Eighth Floor Guy s Tower, Guy s Hospital, London SE1 9RT, United Kingdom
    Proc Natl Acad Sci U S A 100:2041-6. 2003
    ..SAHA dramatically improved the motor impairment in R6/2 mice, clearly validating the pursuit of this class of compounds as HD therapeutics...
  51. ncbi request reprint Histone deacetylase inhibitors: assays to assess effectiveness in vitro and in vivo
    Victoria M Richon
    Discovery Biology, Aton Pharma, Inc, Tarrytown, New York 10591, USA
    Methods Enzymol 376:199-205. 2004
  52. ncbi request reprint Novel histone deacetylase inhibitors in the treatment of thyroid cancer
    Constantine S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Clin Cancer Res 11:3958-65. 2005
    ..g., anaplastic and medullary thyroid carcinomas) for which limited, if any, therapeutic options are available...
  53. pmc Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors
    Melissa J Peart
    The Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne 3002, Victoria, Australia
    Proc Natl Acad Sci U S A 102:3697-702. 2005
    ....
  54. pmc Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma
    R K Lindemann
    Cancer Immunology Program, The Peter MacCallum Cancer Institute, Trescowthick Research Laboratories, St Andrews Place, East Melbourne, Victoria 3002, Australia
    Proc Natl Acad Sci U S A 104:8071-6. 2007
    ..Our studies provide important information regarding the mechanisms of action of HDACi that have broad implications regarding stratification of patients receiving HDACi therapy alone or in combination with other anticancer agents...
  55. ncbi request reprint Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation
    Deborah L Marrocco
    Dame Roma Mitchell Cancer Research Laboratories, Department of Medicine, University of Adelaide, Hanson Institute, Adelaide, South Australia 5000, Australia
    Mol Cancer Ther 6:51-60. 2007
    ..Consequently, combinatorial treatments that target different components of the AR pathway may afford a more effective strategy to control the growth of prostate cancer cells...
  56. pmc Blasts from the past
    Paul A Insel
    J Clin Invest 114:1017-33. 2004
    ....
  57. pmc Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 101:540-5. 2004
    ..These findings highlight the pleiotropic antitumor effects of HDAC inhibition, and provide the framework for future clinical applications of SAHA to improve patient outcome in MM...
  58. ncbi request reprint Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid
    Christopher M Reilly
    Department of Biomedical Sciences and Pathobiology, Virginia Maryland Regional College of Veterinary Medicine, Virginia Polytechnic Institute and State University and Edward Via College of Osteopathic Medicine, Blacksburg, 24060, USA
    J Immunol 173:4171-8. 2004
    ..These data indicate that SAHA blocks mesangial cell inflammatory mediator production in vitro and disease progression in vivo in MRL/lpr mice...